Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in patients with COPD

Background: Two 24-week studies (ACLIFORM, AUGMENT) investigated two fixed-dose combinations (FDCs) of aclidinium bromide/formoterol fumarate in patients with chronic obstructive pulmonary disease (COPD). Both FDCs were found to improve lung function vs placebo and monotherapy components. Aim: To investigate respiratory symptoms in patients with COPD who were participating in ACLIFORM and AUGMENT. Methods: Patients were randomized to placebo, formoterol 12 µg, aclidinium 400 µg, FDC 400/6 µg or FDC 400/12 µg BID. Respiratory symptoms were evaluated by the Transition Dyspnea Index (TDI) focal score, change from b…